Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of PRO1160 in Patients With Metastatic Renal Cell Carcinoma (RCC), Metastatic or Relapsed Nasopharyngeal Carcinoma (NPC), or Advanced (Stage III or IV) Non-Hodgkin Lymphoma (NHL)

NCT05721222 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT05721222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05721222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of PRO1160 in Patients With Metastatic Renal Cell Carcinoma (RCC), Metastatic or Relapsed Nasopharyngeal Carcinoma (NPC), or Advanced (Stage III or IV) Non-Hodgkin Lymphoma (NHL)
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Terminated
Start date
March 15, 2023
Completion date
November 5, 2025
Enrollment
42 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma, non hodgkin lymphoma, renal cell carcinoma